To assess in vivo the effect of WBC100 on c‐Myc overexpressing cancer cells of hematological malignancies, we next established an orthotopic human AML model using NOD/SCID/IL2Rγ‐/‐ (NSG) mice with refractory MOLM‐13‐luciferase cells with high c‐Myc levels. Here, MYC is linked to hematologic disorder.